ANI Pharmaceuticals Files 8-K on Financials

Ticker: ANIP · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1023024

Ani Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form Type8-K
Filed DateNov 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K, disclosure

TL;DR

ANI Pharma dropped an 8-K on Nov 10th - check financials!

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indicates a formal reporting event.

Why It Matters

This 8-K filing signals that ANI Pharmaceuticals is providing updated financial information and disclosures to the public, which is crucial for investors to assess the company's performance and regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial reporting and does not indicate any immediate negative events or significant changes.

Key Players & Entities

  • ANI PHARMACEUTICALS INC (company) — Registrant
  • November 10, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 210 Main Street West Baudette, Minnesota 56623 (address) — Principal Executive Offices
  • BIOSANTE PHARMACEUTICALS INC (company) — Former Company Name
  • BEN ABRAHAM TECHNOLOGIES INC (company) — Former Company Name

FAQ

What specific financial results are being reported in this 8-K?

The provided text for the 8-K filing does not contain specific financial results or figures. It only indicates that the report pertains to 'Results of Operations and Financial Condition'.

What is the significance of filing an 8-K on November 10, 2025?

Filing an 8-K on November 10, 2025, signifies that ANI Pharmaceuticals, Inc. is making a current report available to the public regarding material events or information, including financial condition and results of operations.

What were ANI Pharmaceuticals' former company names?

ANI Pharmaceuticals, Inc. was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.

Where are ANI Pharmaceuticals' principal executive offices located?

ANI Pharmaceuticals, Inc.'s principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.

What is the standard industrial classification for ANI Pharmaceuticals?

ANI Pharmaceuticals, Inc. falls under the Standard Industrial Classification code 2834, which is for Pharmaceutical Preparations.

Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-10 08:45:41

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On November 10, 2025, ANI Pharmaceuticals, Inc. (the "Company") published an updated investor presentation to the investor relations section of its website. The Company may use the updated presentation in various meetings with investors, analysts, and others from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated November 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 10, 2025 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.